Development of universal antidotes to control aptamer activity. - Wikidata - wikimedia - TriplyDB

Development of universal antidotes to control aptamer activity.

Development of universal antidotes to control aptamer activity.

http://www.wikidata.org/entity/Q34433842

about

Aptamers: A Feasible Technology in Cancer Immunotherapy Aptamers: A promising chemical antibody for cancer therapy Nucleic acid aptamers: an emerging frontier in cancer therapy Pathophysiology and Treatments of Oxidative Injury in Ischemic Stroke: Focus on the Phagocytic NADPH Oxidase 2 Aptamers: A New Technological Platform in Cancer Immunotherapy Development of Cell-SELEX Technology and Its Application in Cancer Diagnosis and Therapy Aptamer-Drug Conjugates Selection of an aptamer antidote to the anticoagulant drug bivalirudin A Synthetic Aptamer-Drug Adduct for Targeted Liver Cancer Therapy Modulation of the Coagulation Cascade Using Aptamers An in vivo strategy to counteract post-administration anticoagulant activity of azido-Warfarin.Probing the coagulation pathway with aptamers identifies combinations that synergistically inhibit blood clot formation.The inhibition of anti-DNA binding to DNA by nucleic acid binding polymers.New Technologies Provide Quantum Changes in the Scale, Speed, and Success of SELEX Methods and Aptamer Characterization.Spiegelzymes: sequence specific hydrolysis of L-RNA with mirror image hammerhead ribozymes and DNAzymes.Aptamer photoregulation in vivo Nucleic acid-binding polymers as anti-inflammatory agents Nonclinical evaluation of novel cationically modified polysaccharide antidotes for unfractionated heparin Rapidly regulating platelet activity in vivo with an antidote controlled platelet inhibitor Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane.Aptamers: current challenges and future prospects.Nucleic acid scavengers inhibit thrombosis without increasing bleeding.Polymeric drugs: Advances in the development of pharmacologically active polymers.Targeting Two Coagulation Cascade Proteases with a Bivalent Aptamer Yields a Potent and Antidote-Controllable Anticoagulant.Identification and characterization of an agonistic aptamer against the T cell costimulatory receptor, OX40.Identification of TIM3 2'-fluoro oligonucleotide aptamer by HT-SELEX for cancer immunotherapy.Application of aptamers for targeted therapeutics.Aptamers: problems, solutions and prospects.Nucleic acid aptamer-mediated drug delivery for targeted cancer therapy.A high affinity, antidote-controllable prothrombin and thrombin-binding RNA aptamer inhibits thrombin generation and thrombin activity.Identification of a DNA aptamer that inhibits sclerostin's antagonistic effect on Wnt signalling.Dependence of aptamer activity on opposed terminal extensions: improvement of light-regulation efficiency.Status and Prospects of Aptamers as Drug Components.Nano-antidotes for drug overdose and poisoning.Development of Optimized Inhibitor RNAs Allowing Multisite-Targeting of the HCV Genome.Recent Progress in Aptamer-Based Functional Probes for Bioanalysis and Biomedicine.Spiegelzymes® mirror-image hammerhead ribozymes and mirror-image DNAzymes, an alternative to siRNAs and microRNAs to cleave mRNAs in vivo?Inhibiting the intrinsic pathway of coagulation with a factor XII-targeting RNA aptamer.Scavenging Circulating Mitochondrial DNA as a Potential Therapeutic Option for Multiple Organ Dysfunction in Trauma Hemorrhage.

P2860

Q26740303-AB1B4CAE-78D5-41CF-9CBC-52905A841BF3 Q26766832-85DCADAA-70EB-4316-8D02-4A19986FACE1 Q26849947-BF3AEDAD-9AF0-43AD-840A-B8C888AE6BC6 Q27005956-C3D33972-02F1-401F-B641-81B65CEE47B6 Q28068981-F4A7754A-A081-4EC3-A0EC-40066668A4F2 Q28080168-15489996-BCE2-4B03-A364-28E3790BD44B Q28468281-1700A070-E044-401C-AD43-C0CBD0EBBAC0 Q28487700-511B00B7-44D1-4619-B581-81A20B107F28 Q28550592-C11B4C56-234C-41F1-A887-BA4A021404DE Q28816936-0ACA8F50-BEC1-4D36-B33C-B65BA8D0627B Q33754113-4DEE715A-D944-42D7-8C23-09602D7F4CCE Q34052471-535EB50B-A1BC-4C43-9C37-64ADF4366C82 Q34342476-928CAE09-FAAC-4FFB-BE02-F4C54E869DD2 Q34459376-EF872CEE-12B9-480A-8A0A-D0C1E5CC1A54 Q34575626-5938A0A0-B1F8-4669-BE2F-F97C7BBB7361 Q34661329-1C47DADB-5503-4C65-BF97-D2AEF6973D75 Q35180765-47467C0E-7B08-4DA6-9BB3-D801D660AF30 Q35185880-16A9E316-0D43-46C6-BFE9-7A879D28D252 Q35750010-327ABE85-3896-4C54-999C-63B487755A8D Q35778918-A066AEA0-F7D4-4E7E-A5F1-21B420239B60 Q35859041-7B507FB9-CB60-48DF-98B3-27AA6235ACE5 Q36167707-1CBED647-56F2-431C-B009-4F5774E65189 Q36307604-DCFAFDF7-7ED3-4A4A-B8E7-7163D56590F6 Q36580126-22DA3692-9451-4B80-AA8A-0836D41D86AC Q36603032-B5FEAC0B-1A72-4A35-B96F-7CB743B519D9 Q36782499-13930BC7-DAD9-4F1F-8654-70A492191AA4 Q38096870-7A5C5E4B-2760-4877-BAB6-8637326CE360 Q38181121-BF6907AC-E3BD-4AE3-8E5B-AC92B4A213EF Q38256244-215B6A8D-3810-4EA4-940D-20BBF59AB7A3 Q38327215-A2FE3B96-8B00-45E4-A034-2C5F120A3361 Q38338282-E94E4072-FACF-4CA9-8FD7-F8947EBC055D Q38348058-C7D69796-D971-4AE2-B76C-58FFF6173EAF Q38488502-F07998FC-9CA8-4516-9213-3124BDA1F9D9 Q38515174-7C4C0AA9-59CE-4CD8-B098-03D879CFC948 Q38771180-453671E7-38D2-4007-A869-BBB1D9FEA5BD Q38848925-C39385C0-1720-4617-89DA-64656B9749F1 Q41898699-ADE0C480-DC39-48FA-A042-84F1D4CD0369 Q42922540-AAF51854-66AE-4ED4-A295-7E5937C9078D Q55259402-583FB8AB-D99E-466F-AD86-79A41A288E9E

P2860

Development of universal antidotes to control aptamer activity.

http://www.wikidata.org/entity/Q34433842

description

2009 nî lūn-bûn

@nan

2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Development of universal antidotes to control aptamer activity.

@ast

Development of universal antidotes to control aptamer activity.

@en

Development of universal antidotes to control aptamer activity.

@nl

type

label

Development of universal antidotes to control aptamer activity.

@ast

Development of universal antidotes to control aptamer activity.

@en

Development of universal antidotes to control aptamer activity.

@nl

prefLabel

Development of universal antidotes to control aptamer activity.

@ast

Development of universal antidotes to control aptamer activity.

@en

Development of universal antidotes to control aptamer activity.

@nl

P1433

Q34433842-20DD0440-DD7E-4E51-9487-843103DB3485

P1476

Q34433842-D88C848B-3325-4D92-BB87-0839A25C5D0F

P2093

Q34433842-172FE6BD-3404-4DD9-A913-21C9B774FA3D

Q34433842-3DDF55B8-781F-4F65-A8AF-BAB116E4A102

Q34433842-65565394-0CCA-473D-93A2-6B20422F0763

Q34433842-6C080322-146D-4EB1-A330-9ADDF7123170

Q34433842-8D055782-DB1C-4F60-A12A-C47E55333D80

Q34433842-925E147F-560D-4F22-93EF-E6AF881C19DF

Q34433842-A47CF75A-8C31-4D4D-9C43-4B87B5CAC504

Q34433842-BBB2C972-F41A-4F5C-A623-17505E969841

Q34433842-CDB34EAA-4B22-46FF-80FA-EC19D0A3B31E

Q34433842-EE321113-BC48-4AC0-9B2F-97C648A1853F

P2860

Q34433842-0311D480-7711-48CF-B3F7-732F85DB50E3

Q34433842-04464790-91B7-48E5-B047-5E3CEA22C690

Q34433842-08ECDA38-A3A1-4AA5-AD8E-1B50D9AE04B4

Q34433842-110CE6F4-1DF8-4ACE-8C67-3412C9B4513A

Q34433842-2D4E8922-DE69-4EF0-A705-4A10692E2082

Q34433842-306B5AF9-BA27-467D-9D1E-A433B3A8C330

Q34433842-31022CF2-5FE7-410B-B95D-1B3F85BBBE4C

Q34433842-3B2445FD-2D1E-4190-992B-3ADFD4DE8EA1

Q34433842-3DB26F63-C221-4027-AA30-245BC90AA3A1

Q34433842-415C8B11-E3AE-442A-8A31-B05B27C1F36C

P2888

Q34433842-268176D7-9550-47E0-8BE7-DEC24C92CDCB

P304

Q34433842-29F6B951-C23B-4190-B1B9-C0D0B134A6F1

P31

Q34433842-59B9AB91-2119-4E67-BB67-86965C3116F7

P356

Q34433842-6762D8E0-0A4C-4FD7-A43D-23DF45045B7B

P407

Q34433842-EC003445-41BF-4CE7-AB84-DF77A4813385

P433

Q34433842-CDF1AE4D-37AA-4082-AE0F-7B609281FD68

P478

Q34433842-8D5493A7-76E3-420E-A90D-5B4DB4872594

P50

Q34433842-78B29A72-FAEB-4512-8EF8-F355A3849906

P577

Q34433842-A7AFC716-DB54-492B-ADB6-8C9BCB15F15C

P5875

Q34433842-69600F5F-2F68-43C4-8CBF-9EC83FE824C0

P698

Q34433842-6AE50D20-BFC3-47C1-AF58-8F7C4098DE20

P932

Q34433842-03026A93-410F-494C-BEEC-07E16A7E0672

P356

P1433

Nature Medicine

P1476

Development of universal antidotes to control aptamer activity

@en

P2093

Brendan C Mack

http://www.w3.org/2001/XMLSchema#string

Bruce A Sullenger

http://www.w3.org/2001/XMLSchema#string

Charlene M Blake

http://www.w3.org/2001/XMLSchema#string

George Quick

http://www.w3.org/2001/XMLSchema#string

Jeremy D Heidel

http://www.w3.org/2001/XMLSchema#string

Joanna Yi-Ching Liu

http://www.w3.org/2001/XMLSchema#string

Kristin M Bompiani

http://www.w3.org/2001/XMLSchema#string

Mark E Davis

http://www.w3.org/2001/XMLSchema#string

Ruby T S Lam

http://www.w3.org/2001/XMLSchema#string

Sabah Oney

http://www.w3.org/2001/XMLSchema#string

P2860

Mfold web server for nucleic acid folding and hybridization prediction

Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase

In vitro selection of RNA molecules that bind specific ligands

Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies

Blocking the initiation of coagulation by RNA aptamers to factor VIIa.

Generation of species cross-reactive aptamers using "toggle" SELEX.

Aptamers: an emerging class of therapeutics.

RNA aptamers as reversible antagonists of coagulation factor IXa.

A novel antidote-controlled anticoagulant reduces thrombin generation and inflammation and improves cardiac function in cardiopulmonary bypass surgery.

Allergy to protamine sulfate.

P2888

P304

1224-1228

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NM.1990

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-10-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26868233

http://www.w3.org/2001/XMLSchema#string

P698

19801990

http://www.w3.org/2001/XMLSchema#string

P932

3008622

http://www.w3.org/2001/XMLSchema#string